According to Sanofi, the potential vaccine demonstrates strong immune responses across all adult age groups in Phase 2 trial.
The Phase 2 interim results showed 95 to 100% efficacy following a second injection in all age groups (18 to 95 years old).
“Our Phase 2 data confirm the potential of this vaccine to play a role in addressing this ongoing global public health crisis, as we know multiple vaccines will be needed, especially as variants continue to emerge and the need for effective and booster vaccines, which can be stored at normal temperatures, increases.With these favorable results, we are set to progress to a global Phase 3 efficacy study. We look forward to generating additional data and working with our partners around the world to make our vaccine available as quickly as possible,”Thomas Triomphe, Executive Vice President and Global Head of Sanofi Pasteur said.
If all trials are successful, the vaccine may be approved at the end of 2021.
As we reported earlier, the European Union created the necessary right conditions for a “safe reopening” of tourism in the summer. EU Commissioner for the Internal Market Thierry Breton stated this.
“It is clear that the situation remains difficult. However, I am sure that we finally see light at the end of the tunnel. We now have the right tools and conditions to ensure a safe reopening of the tourism season,” Breton said.